Tortugas Neuroscience, Inc.

Tortugas Neuroscience, Inc. , based in the U. S. , is dedicated to developing innovative therapies aimed at addressing complex brain disorders and enhancing brain health through advanced scientific discoveries.

Founded in 2024, in Framingham, US by Jeff Jonas and Albert Robichaud, Tortugas Neuroscience, Inc. specializes in creating therapies for various neurological conditions. The current CEO is Jeff Jonas. In April 2026, Tortugas Neuroscience, Inc.

raised an undisclosed amount of series A funding co-led by Cure Ventures, The Column Group and AN Ventures Partners. The round was part of a larger USD 106 million seed and series A funding. Tortugas Neuroscience focuses on the development of innovative therapies targeting brain disorders, which include a range of clinical assets aimed at neurological and neuropsychiatric conditions. Their pipeline features products like TRTL-107, TRTL-913, TRTL-729, and TRTL-118, designed to serve healthcare providers, research institutions, and pharmaceutical partners across North America and Europe.

Tortugas Neuroscience generates revenue through partnerships and collaborations with pharmaceutical companies and research institutions, engaging in business-to-business transactions that support the development and commercialization of clinical assets. Revenue sources include milestone payments, licensing agreements, and potential royalties upon commercial success, negotiated through strategic contracts. The company will use the April 2026 funding to advance research and development, including the completion of its Phase 2 trials. The company aims to launch its new products targeting specific neurological challenges while expanding its market reach into Europe.

The recent Series A funding will support these initiatives, facilitating the continued development of their therapeutic pipeline.